Sharp has invested US$650,000 into enhancing its Interactive Response Technology (IRT) solution.
Sharp has invested US$650,000 into enhancing its Interactive Response Technology (IRT) solution, which is employed to manage patient interactions and drug supplies during clinical trials as well as to perform a variety of functions for sponsors, drug depots, and investigative sites.
With this investment, the company is seeking to add a supply forecaster to predict patient enrolment and clinical supply consumption, a warehouse return system to perform accountability for returns from clinical sites, integration with the company’s enterprise resource planning system, and introduction of dynamic randomization with minimization and simulation.
“At Sharp, we want to reduce the cost of clinical trials to the benefit of sponsors and patients,” said Eddie Montoya, newly appointed IRT specialist at Sharp in a press release. “One of the tools that helps us deliver this goal is IRT. The data management side of clinical trials costs around 30% of the overall cost-IRT mitigates this cost by ensuring the integrity of trial data and that data [are] collected and exchanged in the most efficient way possible. IRT also reduces drug waste by ensuring the right amount of drug goes to the right place at the right time. The enhancements to our solution will bolster its performance and help make clinical trials more efficient and reliable, which will lead to savings for our clients around the world.”
Source: Sharp
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Solutions Podcast: Emerging Methods of Vaccine Administration and Distribution
June 20th 2023Michael Schrader, CEO and co-founder of Vaxess, discusses the latest on vaccine administration and different ways the pharmaceutical industry can distribute these products with Pharmaceutical Technology editor Jill Murphy.
Exosomes Field Advances with Milestones Achieved by EXO Biologics and ExoXpert
December 4th 2024EXO Biologics and ExoXpert, an EXO Biologics subsidiary, have received GMP certification of a European manufacturing facility for exosomes and have successfully loaded mRNA and DNA payloads into GMP-grade exosomes for drug delivery.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Solutions Podcast: Emerging Methods of Vaccine Administration and Distribution
June 20th 2023Michael Schrader, CEO and co-founder of Vaxess, discusses the latest on vaccine administration and different ways the pharmaceutical industry can distribute these products with Pharmaceutical Technology editor Jill Murphy.
Exosomes Field Advances with Milestones Achieved by EXO Biologics and ExoXpert
December 4th 2024EXO Biologics and ExoXpert, an EXO Biologics subsidiary, have received GMP certification of a European manufacturing facility for exosomes and have successfully loaded mRNA and DNA payloads into GMP-grade exosomes for drug delivery.
2 Commerce Drive
Cranbury, NJ 08512